Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 11/2005

01-11-2005 | Review

Latent autoimmune diabetes in adults (LADA) should be less latent

Authors: S. Fourlanos, F. Dotta, C. J. Greenbaum, J. P. Palmer, O. Rolandsson, P. G. Colman, L. C. Harrison

Published in: Diabetologia | Issue 11/2005

Login to get access

Abstract

‘Latent autoimmune diabetes in adults’ (LADA) is the term coined to describe adults who have a slowly progressive form of autoimmune or type 1 diabetes that can be treated initially without insulin injections. The diagnosis of LADA is currently based on three clinical criteria: (1) adult age at onset of diabetes; (2) the presence of circulating islet autoantibodies, which distinguishes LADA from type 2 diabetes; and (3) insulin independence at diagnosis, which distinguishes LADA from classic type 1 diabetes. The prevalence of LADA in adults presenting with non-insulin-requiring diabetes is approximately 10%. Recognition of LADA expands the concept and prevalence of autoimmune diabetes, but LADA remains poorly understood at both a clinical and research level. In this perspective, we review the nomenclature, diagnostic criteria, genetics, pathology and therapy of LADA, to arrive at recommendations that might advance knowledge and management of this form of diabetes.
Literature
1.
Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359–362PubMed
2.
Genovese S, Bonifacio E, McNally JM et al (1992) Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35:385–388CrossRefPubMed
3.
Gianani R, Pugliese A, Bonner-Weir S et al (1992) Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 41:347–353PubMed
4.
Hagopian WA, Karlsen AE, Gottsater A et al (1993) Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64 K autoantibody positivity at onset predicts diabetes type. J Clin Invest 91:368–374PubMed
5.
Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350:1288–1293CrossRefPubMed
6.
Lohmann T, Nietzschmann U, Kiess W (2000) ‘Lady-like’: is there a latent autoimmune diabetes in the young? Diabetes Care 23:1707–1708PubMed
7.
Juneja R, Palmer JP (1999) Type 1 1/2 diabetes: myth or reality? Autoimmunity 29:65–83PubMed
8.
Palmer JP, Hirsch IB (2003) What’s in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 26:536–538PubMed
9.
Pozzilli P, Di Mario U (2001) Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24:1460–1467PubMed
10.
Hosszufalusi N, Vatay A, Rajczy K et al (2003) Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452–457PubMed
11.
Douek IF, Gillespie KM, Bingley PJ, Gale EA (2002) Diabetes in the parents of children with Type I diabetes. Diabetologia 45:495–501CrossRefPubMed
12.
Cosentino A, Gambelunghe G, Tortoioli C, Falorni A (2002) CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann N Y Acad Sci 958:337–440PubMed
13.
Tuomi T, Carlsson A, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMed
14.
Takeda H, Kawasaki E, Shimizu I et al (2002) Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25:995–1001PubMed
15.
Gjessing HJ, Matzen LE, Pedersen PC, Faber OK, Froland A (1998) Insulin requirement in non-insulin-dependent diabetes mellitus: relation to simple tests of islet B-cell function and insulin sensitivity. Diabet Med 5:328–332
16.
Leslie RD, Pozzilli P (1994) Type I diabetes masquerading as type II diabetes. Possible implications for prevention and treatment. Diabetes Care 17:1214–1219PubMed
17.
Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667–674CrossRefPubMed
18.
Carlsson A, Sundkvist G, Groop L, Tuomi T (2000) Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85:76–80CrossRefPubMed
19.
Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI (2004) Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53:3193–3200PubMed
20.
Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M (1989) A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 320:881–886PubMed
21.
Caillat-Zucman S, Garchon HJ, Timsit J et al (1992) Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242–2250PubMed
22.
Tait BD, Harrison LC, Drummond BP, Stewart V, Varney MD, Honeyman MC (1995) HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum Immunol 42:116–122CrossRefPubMed
23.
Cerna M, Novota P, Kolostova K et al (2003) HLA in Czech adult patients with autoimmune diabetes mellitus: comparison with Czech children with type 1 diabetes and patients with type 2 diabetes. Eur J Immunogenet 30:401–407CrossRefPubMed
24.
Bennett ST, Lucassen AM, Gough SC et al (1995) Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 9:284–292CrossRefPubMed
25.
Pugliese A, Zeller M, Fernandez A Jr et al (1997) The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15:293–297CrossRefPubMed
26.
Vafiadis P, Bennett ST, Todd JA et al (1997) Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 15:289–292CrossRefPubMed
27.
Matejkova-Behanova M, Vankova M, Hill M et al (2004) Polymorphism of INS VNTR is associated with glutamic acid decarboxylase antibodies and postprandial C-peptide in patients with onset of diabetes after 35 years of age. Physiol Res 53:187–190PubMed
28.
Cerrone GE, Caputo M, Lopez AP et al (2004) Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults. Mol Diagn 8:43–49PubMed
29.
Gambelunghe G, Ghaderi M, Tortoioli C et al (2001) Two distinct MICA gene markers discriminate major autoimmune diabetes types. J Clin Endocrinol Metab 86:3754–3760CrossRefPubMed
30.
Vatay A, Rajczy K, Pozsonyi E et al (2002) Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol Lett 84:109–115CrossRefPubMed
31.
Vauhkonen I, Niskanen L, Knip M et al (2000) Impaired insulin secretion in non-diabetic offspring of probands with latent autoimmune diabetes mellitus in adults. Diabetologia 43:69–78CrossRefPubMed
32.
Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710PubMed
33.
Verge CF, Stenger D, Bonifacio E et al (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. diabetes 47:1857–1866PubMed
34.
Harrison LC (2001) Risk assessment, prediction and prevention of type 1 diabetes. Pediatric Diabetes 2:71–82CrossRefPubMed
35.
Kobayashi T, Tanaka S, Okubo M, Nakana, Murase T, Lernmark A (2003) Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. J Clin Endocrinol Metab 88:4678–4775CrossRef
36.
Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP (1999) Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 48:983–988PubMed
37.
Shimada A, Imazu Y, Morinaga S et al (1999) T-cell insulitis found in anti-GAD65+diabetes with residual beta-cell function. A case report. Diabetes Care 22:615–617PubMed
38.
Weetman AP (2003) Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 148:1–9CrossRefPubMed
39.
Smith CM, Clarke CF, Porteous LE, Elsori H, Cameron DJ (2000) Prevalence of coeliac disease and longitudinal follow-up of antigliadin antibody status in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 1:199–203CrossRefPubMed
40.
Wagner R, Genovese S, Bosi E et al (1994) Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia 37:365–371PubMed
41.
Radetti G, Paganini C, Gentili L et al (1995) Frequency of Hashimoto’s thyroiditis in children with type 1 diabetes mellitus. Acta Diabetol 32:121–124CrossRefPubMed
42.
Hansen D, Bennedbaek FN, Hansen LK, Hoier-Madsen M, Jacobsen BB, Hegedus L (1999) Thyroid function, morphology and autoimmunity in young patients with insulin-dependent diabetes mellitus. Eur J Endocrinol 140:512–518PubMed
43.
Gambelunghe G, Forini F, Laureti S et al (2000) Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 52:565–573CrossRef
44.
Kucera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M (2003) Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clin Exp Immunol 133:139–143CrossRefPubMed
45.
Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G (1993) Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902–910PubMed
46.
Kobayashi T, Nakanishi K, Murase T, Kosaka K (1996) Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622–626PubMed
47.
Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G et al (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes/Metab Res Rev 16:442–447CrossRef
48.
Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G (2001) High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032–3038CrossRefPubMed
49.
Behme MT, Dupre J, Harris SB, Hramiak I, Mahon JL (2003) Insulin resistance in latent autoimmune diabetes of adulthood. Ann N Y Acad Sci 1005:374–377CrossRefPubMed
50.
Isomaa B, Almgren P, Henricsson M et al (1999) Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 22:1347–1353PubMed
51.
Baum P, Hermann W, Verlohren HJ, Wagner A, Lohmann T, Grahmann F (2003) Diabetic neuropathy in patients with ‘latent autoimmune diabetes of the adults’ (LADA) compared with patients with type 1 and type 2 diabetes. J Neurol 250:682–687CrossRefPubMed
52.
The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523
53.
Ridker PM (2003) High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92:17K–22KCrossRefPubMed
54.
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
55.
UK Prospective Diabetes Study (UKPDS) Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569
56.
Maruyama T, Shimada A, Kanatsuka A et al (2003) Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 1005:362–369CrossRefPubMed
57.
Uusitupa M, Louheranta A, Lindstrom J et al (2000) The finnish diabetes prevention study. Br J Nutr 83(Suppl 1):S137–S142PubMed
58.
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
Metadata
Title
Latent autoimmune diabetes in adults (LADA) should be less latent
Authors
S. Fourlanos
F. Dotta
C. J. Greenbaum
J. P. Palmer
O. Rolandsson
P. G. Colman
L. C. Harrison
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1960-7

Other articles of this Issue 11/2005

Diabetologia 11/2005 Go to the issue

Article

Associations of TV viewing and physical activity with the metabolic syndrome in Australian adults

Article

Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes

Article

Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study

Article

Role of AMP-activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle

Review

Oestrogens and insulin secretion

Short communication

Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits